Multiple System Atrophy Market Size was approximately USD 84 million in 2020

The Multiple System Atrophy Market reports provide current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM MSA market size from 2019 to 2032. The report also covers current Multiple System Atrophy treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.

With the expected launch of emerging therapies, the multiple system atrophy market is expected to show positive growth in the forecast period in the 7MM. Moreover, increased awareness of MSA has amplified drug research and development.

Key takeaways from the Multiple System Atrophy Market

• As per DelveInsight analysis, the multiple system atrophy market size in the 7MM was approximately USD 125 million in 2021.
• The leading multiple system atrophy companies such as Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others.
• Promising multiple system atrophy therapies in the pipeline include Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH434, and others.
• According to DelveInsight estimates, based on type, there were around 21,000 cases of MSA-P, while for MSA-C, around 15,000 cases were estimated in the 7MM in 2022.

Discover which therapies are expected to grab the major multiple system atrophy market share @ Multiple System Atrophy Market Report

Multiple System Atrophy Overview

Multiple system atrophy (MSA) is a rare, rapidly progressing, fatal neurodegenerative disorder of uncertain etiology that is clinically characterized by a variable combination of Parkinsonism, cerebellar impairment, and autonomic and motor dysfunctions. Depending on the predominant clinical phenotype, the disease is sub-classified into a parkinsonian variant (MSA-P) associated with SND, a cerebellar (MSA-C) variant with OPCA with predominant cerebellar features, and a combination of both forms referred to as “mixed” MSA.

Multiple System Atrophy Epidemiology Segmentation in the 7MM

• Multiple System Atrophy Diagnosed Prevalent Cases
• Multiple System Atrophy Gender-specific Diagnosed Prevalent Cases
• Multiple System Atrophy Age-specific Diagnosed Prevalent Cases
• Multiple System Atrophy Type-specific Diagnosed Prevalent Cases

Download the report to understand which factors are driving multiple system atrophy epidemiology trends @ Multiple System Atrophy Epidemiological Insights

Multiple System Atrophy Treatment Market 

The approved multiple system atrophy market segment includes NORTHERA (droxidopa), the world’s first approved therapy for symptomatic nOH. Dainippon Sumitomo Pharma (DSP) developed it and commercialized it in Japan in 1989. DSP sold the drug license to Chelsea Therapeutics International in 2006. Chelsea received accelerated approval for NORTHERA from the US FDA in February 2014 for symptomatic benefit in adult patients with nOH, and exclusivity will expire in February 2021. nOH is found in approximately 66-90% of MSA patients and is a major cause of disability and injury in the disease.

Multiple System Atrophy Pipeline Therapies and Key Companies

• Lu AF82422: H Lundbeck A/S
• Ampreloxetine (TD-9855): Theravance Biopharma
• AAV2-GDNF Gene Therapy: Brain Neurotherapy Bio, Inc.
• ION464: Ionis Pharmaceuticals, Inc
• ATH434: Alterity Therapeutics

Multiple System Atrophy Market Dynamics

In recent years, there has been a greater understanding of the neuropathological aspects underlying MSA driving the multiple system atrophy market. Because of the numerous clinical features associated with MSA, tremendous effort is being made to develop reliable clinical criteria for diagnosis. The emerging pipeline has the potential for rapid development, and many therapies are in early and mid-stage trials, with approval changing the dynamics of the multiple system atrophy market.

Learn more about the FDA-approved drugs for multiple system atrophy treatment @ Drugs for Multiple System Atrophy Treatment

Scope of the Multiple System Atrophy Market Report

• Coverage- 7MM
• Companies- Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others.
• Pipeline Therapies- Lu AF82422, Ampreloxetine (TD-9855), AAV2-GDNF Gene Therapy, ION464, ATH43, and others
• Multiple System Atrophy Market Dynamics: Multiple System Atrophy Market Barriers and Drivers

Discover more about drugs for multiple system atrophy in development @ Multiple System Atrophy Ongoing Clinical Trials Analysis

Table of Content

1. Key Insights
2. Report Introduction
3. Multiple System Atrophy Market Overview at a Glance
4. Multiple System Atrophy Market: Future Perspective
5. Executive Summary of Multiple System Atrophy (MSA)
6. Key Events
7. Disease Background and Overview: Multiple System Atrophy (MSA)
8. Epidemiology and Patient Population
9. Patient Journey
10. Emerging Drugs
11. Multiple System Atrophy (MSA): Seven Major Market Analysis
12. Key Opinion Leaders’ View
13. Market Drivers
14. Market Barriers
15. SWOT Analysis
16. Unmet Needs
17. Reimbursement and Market Access
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

To know more about multiple system atrophy treatment options, visit Multiple System Atrophy Treatment Drugs

Trending Market Research Reports in 2023 | DelveInsight

1. Technical due diligence
2. Monoclonal Gammopathy of undetermined significance market
3. Stem cell market
4. Varicose vein treatment devices market
5. Oncolytic virus cancer therapy pipeline
6. Scabies market
7. Technical due diligence firms
8. Schistosomiasis market
9. Lactose intolerance market
10. Axillary hyperhidrosis market
11. Cold agglutinin disease market
12. Complement 3 Glomerulopathy market
13. Immune checkpoints activator companies
14. Moderate psoriasis market
15. Nocturia market
16. Parainfluenza virus infection market
17. Polymyalgia Rheumatica market
18. Presbyopia market
19. Secondary progressive multiple sclerosis SPMS market
20. Shigella infections market
21. Smallpox market
22. Spinocerebellar ataxia market
23. Thymidine kinase 2 deficiency market
24. Coronary Microvascular dysfunction CMD market
25. Drug-resistant epilepsy market
26. Pertussis market
27. Hypoxic ischemic encephalopathy market
28. Trichotillomania market
29. Myopia progression market
30. Temporomandibular disorders market
31. Immune thrombocytopenia market
32. Spondylolisthesis market
33. Supraventricular tachycardia market
34. Tay-sachs disease market
35. Varicella zoster HHV 3 infections market
36. X-linked retinitis Pigmentosa market
37. Progressive Supranuclear palsy market report
38. Sly syndrome Market
39. Erosive hand osteoarthritis market
40. Coronary stents pipeline

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com